13075_2021_2709_MOESM2_ESM.pptx (70.74 kB)
Additional file 2 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
presentation
posted on 2022-01-06, 04:29 authored by Cindy Orvain, Anne Cauvet, Alexis Prudent, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Fanny Duhalde, Carole Nicco, Frédéric Batteux, Jérôme Avouac, NingXin Wang, Michelle A. Seaberg, Stacey R. Dillon, Yannick AllanoreAdditional file 2: Supplementary Figure 1. Experimental design of acazicolcept (ALPN-101) treatment in HOCL-induced dermal fibrosis mice. 6-week-old BALB/C female mice were divided into three groups treated with : PBS (n=6), HOCL + Fc control (n=8), or HOCL + acazicolcept (n=8). Dermal fibrosis was induced by subcutaneous HOCL injections five days per week from day 1 to day 42. Test articles (Fc control or acazicolcept) were injected intraperitoneally twice a week. Mice were euthanized 42 days after the first HOCL injection and dorsal skin was collected.
